Skip to main content
Journal of Virology logoLink to Journal of Virology
. 2006 Sep;80(18):9244–9258. doi: 10.1128/JVI.00945-06

Genome of Horsepox Virus

E R Tulman 1,2,3, G Delhon 1,4,5, C L Afonso 1,6, Z Lu 1, L Zsak 1, N T Sandybaev 7, U Z Kerembekova 7, V L Zaitsev 7, G F Kutish 1,5,6, D L Rock 1,5,*
PMCID: PMC1563943  PMID: 16940536

Abstract

Here we present the genomic sequence of horsepox virus (HSPV) isolate MNR-76, an orthopoxvirus (OPV) isolated in 1976 from diseased Mongolian horses. The 212-kbp genome contained 7.5-kbp inverted terminal repeats and lacked extensive terminal tandem repetition. HSPV contained 236 open reading frames (ORFs) with similarity to those in other OPVs, with those in the central 100-kbp region most conserved relative to other OPVs. Phylogenetic analysis of the conserved region indicated that HSPV is closely related to sequenced isolates of vaccinia virus (VACV) and rabbitpox virus, clearly grouping together these VACV-like viruses. Fifty-four HSPV ORFs likely represented fragments of 25 orthologous OPV genes, including in the central region the only known fragmented form of an OPV ribonucleotide reductase large subunit gene. In terminal genomic regions, HSPV lacked full-length homologues of genes variably fragmented in other VACV-like viruses but was unique in fragmentation of the homologue of VACV strain Copenhagen B6R, a gene intact in other known VACV-like viruses. Notably, HSPV contained in terminal genomic regions 17 kbp of OPV-like sequence absent in known VACV-like viruses, including fragments of genes intact in other OPVs and approximately 1.4 kb of sequence present only in cowpox virus (CPXV). HSPV also contained seven full-length genes fragmented or missing in other VACV-like viruses, including intact homologues of the CPXV strain GRI-90 D2L/I4R CrmB and D13L CD30-like tumor necrosis factor receptors, D3L/I3R and C1L ankyrin repeat proteins, B19R kelch-like protein, D7L BTB/POZ domain protein, and B22R variola virus B22R-like protein. These results indicated that HSPV contains unique genomic features likely contributing to a unique virulence/host range phenotype. They also indicated that while closely related to known VACV-like viruses, HSPV contains additional, potentially ancestral sequences absent in other VACV-like viruses.


The genus Orthopoxvirus includes members of the family Poxviridae historically relevant to human health—variola virus (VARV), the etiologic agent of smallpox, and vaccinia virus (VACV), the vaccine virus used to eradicate smallpox (32). Other orthopoxviruses (OPVs), similar to VACV, are zoonotic and significant for human health, including monkeypox virus (MPXV) and cowpox virus (CPXV) (33). Still others, similar to VARV, remain restricted to specific, albeit nonhuman, hosts, including camelpox virus (CMLV) in camels and ectromelia virus (ECTV) in mice. Recent developments have heightened interest in OPV virulence and host range, including the threats of deliberate VARV reintroduction, virulence associated with preemptive smallpox vaccination and use of VACV-based recombinant vaccines, and the introduction of MPXV into the United States (16, 28, 69, 83). Isolation of OPV from infected animals and humans during limited disease outbreaks or from animals in the wild suggests that additional OPVs circulating in nature could represent an emerging disease threat (24, 25, 27, 32, 46, 49, 50, 90).

Given their importance, OPVs have been extensively studied as models of poxviral molecular biology, genomics, genetics, and virus-host interaction (19, 33, 59). Research has revealed that OPVs contain approximately 170 to 230 genes, with those in central genomic regions generally involved in poxviral intracytoplasmic replication and those in terminal genomic regions involved or potentially involved in virus-host interactions, including manipulation of host immune or cellular apoptotic responses (4, 19, 59, 60, 82, 87).

Comparative analysis of completely sequenced OPV genomes, including most known OPV species and several strains of VARV, VACV and the closely related rabbitpox virus (RPXV), MPXV, CMLV, and CPXV has begun to reveal the degree of variability within the genus Orthopoxvirus, verifying that terminal genomic regions are the most variable and thus likely to contribute to the virulence and host range characteristics of different OPVs (2, 9, 21, 22, 36, 39, 51, 52, 54, 58, 78, 80, 81). The precise roles and contributions of many variable genes and gene complements in OPV virulence and host range, however, remain to be fully characterized. It is likely that complete genomic data from uncharacterized OPV isolates will aid in OPV gene identification and functional characterization, while also providing information regarding the pathogenic potential of the virus.

Horsepox virus (HSPV) is an OPV causing horsepox, classically known as a poxviral disease of horses. Although common before the 20th century, horsepox is rare today to the point of being considered extinct (14, 44). Multiple clinical forms of horsepox have been described, including a benign, localized form involving lesions in the muzzle and buccal cavity known previously as contagious pustular stomatitis and a generalized, highly contagious form known as equine papular stomatitis (44, 94). Horsepox has also been associated with an exudative dermatitis of the pasterns described as “grease” or grease heel, a clinical syndrome also associated with other infectious and environmental agents (14, 33, 94). Horsepox is differentiated clinically from two other poxviral diseases of horses, equine molluscum contagiosum and Uasin Gishu disease. Equine molluscum contagiosum is a mild, self-limiting cutaneous disease similar to the human disease and is associated with a virus similar to molluscum contagiosum virus (88, 94). Uasin Gishu disease has been described in nonindigenous horses of eastern Africa and is associated with a poorly characterized OPV; however, generalized skin lesions are proliferative and papillomatous and the disease may be chronic in nature (33, 88, 94). HSPV is yet to be characterized molecularly, with no DNA sequence information available. Given the interest in understanding the genetic basis of viral host range and virulence and the relationships between OPVs, we have sequenced and analyzed the genome of a pathogenic field isolate of HSPV.

MATERIALS AND METHODS

Viral DNA isolation, cloning, sequencing, and sequence analysis.

The HSPV strain MNR-76 was isolated from sick horses in Bayan-somon of Khentei aimak, Mongolia, in 1976. MNR-76 causes severe disease in horses of the Mongolian breed, including pyrexia, pustular stomatitis with occasional lesions on udders and ears, and especially severe disease in foals and mares, in which death was noted (S. M. Mamadaliyev, personal communication). Viruses were passaged twice in sheep kidney cells, from which viral genomic DNA was extracted as previously described (93). Random DNA fragments were obtained by incomplete enzymatic digestion with Tsp509I endonuclease, cloned into the dephosphorylated EcoRI site of pUC19 plasmids, and grown in Escherichia coli DH10B cells (Gibco BRL, Gaithersburg, Md.). Double-stranded DNA templates were purified and sequenced from both ends with M13 forward and reverse primers using dideoxy chain terminator sequencing chemistries and the Applied Biosystems PRISM 3700 automated DNA sequencer (Applied Biosystems, Foster City, CA). Chromatogram traces were base called with Phred (30), which also produced a quality file containing a predicted probability of error at each base position. The sequences were assembled with Phrap (29) and CAP3 (43) using quality files and default settings to produce a consensus sequence with some subsequent manual editing using the Consed sequence editor (37). Gap closure was achieved by primer walking of gap-spanning clones and sequencing of PCR products. Final DNA consensus sequences represented on average sevenfold redundancy at each base position, contained no obvious polymorphisms, and demonstrated a Consed estimated error rate of less than 0.01 error per 10 kb.

Sequence analysis was conducted essentially as previously described (1). Briefly, DNA composition, structure, repeats, and restriction enzyme patterns were analyzed and open reading frame (ORF) maps created using EMBOSS (70), GCG v.10 (Accelrys, Inc., San Diego, CA), and MacVector (Accelrys, Inc) software packages. ORFs longer than 30 amino acids with a methionine start codon were evaluated for coding potential using the GLIMMER (71) computer program, and those greater than 60 amino acids were subjected to similarity searches against nonredundant protein databases and redundant viral protein databases using BLAST (8) and against viral nucleotide databases using TFASTA and TFASTX (65, 66). Here, 236 ORFs were annotated and numbered from left to right, with alphabetic subordering given to indicate multiple potential fragments of larger OPV ORFs. Given the predicted nature of all HSPV genes and gene products, ORF names were used throughout the text to indicate both the predicted gene and its putative protein product. Genomic, subgenomic, and protein alignments and comparisons were done using DIALIGN v2.2.1 (57) using anchors as generated by CHAOS (17), Multi-LAGAN (18), CLUSTAL W (89), BLAST, FASTA (64), SEAVIEW (34), and DOTTER (84) programs. Phylogenetic analyses were conducted on whole-genome sequences and genomic subregions, including a central region used previously for OPV phylogenetic analysis (positions 26800 to 170171) (22, 51), using PHYLIP (31); PHYLO_WIN (34), TREE-PUZZLE (73), and PHYML (40) programs, with evolutionary models selected using MrModeltest 2.2 (62) and additional analyses conducted on alignments in which poorly aligned regions were removed with Gblocks (20).

Nucleotide sequence accession number.

The HSPV MNR-76 genome sequence has been deposited in GenBank under accession no. DQ792504.

RESULTS AND DISCUSSION

Organization of the HSPV genome.

HSPV MNR-76 genome sequences were assembled into a contiguous sequence of 212,633 bp. The leftmost nucleotide was arbitrarily designated base 1. Similar to other OPVs, the HSPV genome contained 69% A+T nucleotide composition and a central coding region bounded by two identical inverted terminal repeat (ITR) regions.

HSPV ITRs were 7,527 bp and contained elements similar to repetitive and nonrepetitive sequences characterized in other OPVs, including a portion of the terminal hairpin loop-like sequence (positions 1 to 15 from each terminus) and nonrepetitive region 1 (NR1) (positions 21 to 101 from each terminus) and concatemer resolution (position 21 to 40 from each terminus) sequences identical to those present in VACV strain Copenhagen (CPN) (11, 36, 55). Notably, HSPV lacked extensive tandem repetition of terminally located sequences, containing only single copies of the 69-bp (positions 102 to 170, 100% identical to CPN) and 54-bp (positions 518 to 571, 96% identical to CPN) motifs repeated 8.5 to 42 times in VACV strains and RPXV (9, 10, 36, 51). Incomplete copies of 69-bp (positions 171 to 188), 54-bp (positions 572 to 601), and VACV 125-bp repeat-like (positions 494 to 517) motifs flanked complete 69-bp and 54-bp motifs, which were also separated from each other by an NR2-like sequence (positions 189 to 493, 92% identity to CPN positions 2867 to 3171). The HSPV ITR contained eight ORFs initiating and terminating in the ITR, with HSPV001/HSPV207 encompassing the 54-bp and 125-bp motif region (Table 1 ) . These data indicate that while similar to VACV in regions of the ITR, HSPV organizationally resembles other OPVs such as VARV, MPXV, and ECTV which contain fewer or single complete tandem repeat units in their termini (21, 53, 81).

TABLE 1.

HSPV ORFs in terminal genomic regions compared to best-matching ORFs annotated in VACVs, RPXV, and CPXVsa

HSPV ORF Position (lengthb) VACVc
RPXVd
CPXVe
Putative function/similarityh
CPN
WR
Tian
MVA
mO
ORF Length GRI
BRI
ORF Length % Idf ORF Length ORFg Length ORF Length ORF Length ORF Length % Idf ORF Length
Left-terminal genomic region
HSPV001 688-473 (72) 001 64
HSPV002 1547-804 (248) C23L 244 86 001 244 C20L 244 001L 136 L10L 258 001 258 D1L 255 87 003 246 Chemokine binding protein
HSPV003 2723-1676 (349) C22L 122 91 002 61 002L 176 L09L 34 63 D2L 351 95 005 355 TNFR II-like protein, CrmB
004 122 L08L 122 122
HSPV004 4570-2810 (587) C21L 113 100 005 48 L07L 48 113 D3L 586 95 006 619 Ankyrin repeat protein
C20L 103 69 006 64 L06L 128 109
C19L 259 90 007 109 L04L 109 77
008 112 149
HSPV005a 5051-4779 (91) L03L 93 D4L 672 97 008 672 Ankyrin repeat protein
HSPV005b 5530-5081 (150) C18L 150 98 L03L 93 163 D4L 672 92 008 672
HSPV005c 6797-5607 (397) C17L 386 92 003L 102 L02L 416 385 D4L 672 94 008 672
004L 233
HSPV006 7419-6961 (153) C16L 181 97 189R 188 L01L 147 002 184 D5L 153 97 009 153
HSPV007 8041-7589 (151) D6L 219 76 010 215
HSPV008 9327-8509 (273) D7L 273 89 BTB/POZ domain protein
HSPV009 10133-9681 (151) D12L 202 96 014 202 Chemokine binding domain protein
HSPV010 10529-10197 (111) D13L 111 99 015 110 TNFR, CD30-like protein
HSPV011a 11413-10625 (263) D14L 764 95 016 764 Ankyrin repeat protein
HSPV011b 12197-11334 (288) D14L 764 95 016 764
HSPV011c 12637-12191 (149) D14L 764 97 016 764
HSPV012 14485-13175 (437) C1L 437 97 017 435 Ankyrin repeat protein
HSPV013 15127-14852 (92) C2L 178 98 018 171
HSPV014a 15498-15220 (93) C3L 833 95 019 796 Ankyrin repeat protein
HSPV014b 16216-15473 (248) C3L 833 94 019 796
HSPV014c 16975-16367 (203) C3L 833 94 019 796
HSPV014d 17605-17111 (165) C3L 833 89 019 796
HSPV015a 17913-17695 (73) C4L 170 91 020 170 VACV C7L-like protein
HSPV015b 18205-17960 (82) C4L 170 94 020 170
HSPV016 18365-18784 (140) C11R 142 95 009 140 C18R 140 005R 140 005R 140 006 138 C5R 138 88 021 139 Growth factor
HSPV017 19934-18942 (331) C10L 331 96 010 331 C17L 331 006L 326 007L 331 007 331 C6L 331 96 022 331
HSPV018 20448-20765 (106) 011 181 C16R 44 007R 91 008R 239 008 242 C7R 242 88 023 242 ECTV p28-like host range protein
HSPV019 21707-21330 (126) 013 126 C15L 68 008L 120 009L 124 009 126 C8L 124 78 024 126 Secreted IL-18 binding protein
HSPV020a 22038-21769 (90) 014 237 009L 90 010L 90 409 C9L 668 96 025 668 Ankyrin repeat host range protein
HSPV020b 22479-22054 (142) 014 237 C14L 142 010L 142 011L 142 409 C9L 668 95 025 668
HSPV020c 22999-22571 (143) 015 137 C13L 115 011L 135 012L 137 409 C9L 668 97 025 668
HSPV020d 23508-23278 (77) 016 77 C12L 77 012L 90 013L 77 77 C9L 668 91 025 668
HSPV020e 23745-23533 (71) 017 71 C11L 76 013L 71 014L 71 71 C9L 668 95 025 668
HSPV021 24072-23884 (63) 018 60 C10L 59 59 59 010 59 C10L 62 95 026 68
HSPV022 26149-24248 (634) C9L 634 99 019 634 C9L 634 014L 109 016L 634 011 634 C11L 614 69 027 632 Ankyrin repeat protein
015L 96
016L 297
HSPV023 26725-26195 (177) C8L 184 89 020 177 C8L 177 017L 177 019L 177 012 177 C12L 182 88 028 186
HSPV024 27249-26800 (150) C7L 150 97 021 150 C7L 150 018L 150 020L 150 013 150 C13L 150 97 029 150 Host range protein
HSPV025 27949-27485 (155) C6L 151 89 022 151 C6L 151 019L 157 021L 151 014 151 C14L 156 96 030 155
HSPV026a 28280-28089 (64) C5L 204 98 023 204 C5L 204 022L 204 015 204 C15L 205 98 031 69
HSPV026b 28690-28328 (121) C5L 204 98 023 204 C5L 204 022L 204 015 204 C15L 205 96 032 125 BTB/POZ domain protein
HSPV027a 29175-28765 (137) C4L 316 97 024 316 C4L 255 023L 316 016 316 C16L 316 97 033 316
HSPV027b 29689-29489 (67) C4L 316 98 024 316 C4L 255 023L 316 016 316 C16L 315 93 033 316
HSPV028 30547-29759 (263) C3L 263 96 025 263 C3L 263 025L 263 017 263 C17L 259 93 034 263 Complement binding protein
HSPV029 32153-30618 (512) C2L 512 97 026 512 C2L 512 026L 512 018 512 C18L 512 97 035 512 Kelch-like protein
HSPV030 32891-32223 (223) C1L 224 97 027 229 C1L 224 027L 224 019 224 C19L 231 96 036 231
HSPV031 33231-32881 (117) N1L 117 100 028 117 NIL 117 020L 113 028L 117 020 117 Q1L 117 94 037 117 TLR/IL-1R/TNFR signaling inhibitor
HSPV032 33895-33371 (175) N2L 175 97 029 175 N2.1L* 175 021L 170 029L 175 021 176 Q2L 175 98 038 177 Alpha-amanitin-sensitive protein
HSPV033a 34155-33940 (72) M1L 472 94 030 472 M1L 472 030L 472 022 472 P1L 474 93 039 473 Ankyrin repeat protein
HSPV033b 34798-34148 (217) M1L 472 97 030 472 M1L 472 030L 472 022 472 P1L 474 97 039 473
HSPV033c 35347-34871 (159) M1L 472 96 030 472 M1L 472 030L 472 022 472 P1L 474 93 039 473
HSPV034 35987-35328 (220) M2L 220 99 031 220 M2L 196 031L 220 023 220 P2L 163 99 040 220
HSPV035 36976-36125 (284) K1L 284 97 032 284 K1L 189 022L 98 032L 284 024 284 M1L 284 95 041 284 Ankyrin repeat host range protein
HSPV036 38328-37210 (373) K2L 369 97 033 369 K2L 369 023L 369 035L 369 025 369 M2L 378 97 042 373 Serpin SPI-3
HSPV037 38644-38381 (88) K3L 88 96 034 88 K3L 88 024L 88 037L 88 026 88 M3L 88 97 043 88 eIF2α-like PKR inhibitor
HSPV038 39979-38708 (424) K4L 424 99 035 424 K5L* 424 025L 424 038L 424 027 424 M4L 424 97 044 424 Phospholipase D-like protein
HSPV039 40845-40159 (229) K5L 136 95 037 134 K6L 134 026L 170 040L 134 121 M5L 276 94 045 276 Monoglyceride lipase
K6L 81 96 038 81 041L 84 84
HSPV040 40984-41430 (149) K7R 149 100 039 140 K8R 140 028R 149 042R 140 028 149 M6R 161 96 046 149
HSPV041 42262-41501 (254) F1L 226 88 040 226 F1L 226 029L 222 044L 226 029 227 G1L 238 85 048 251 Apoptosis inhibitor
HSPV042 42717-42277 (147) F2L 147 98 041 147 F2L 147 030L 147 045L 147 030 147 G2L 147 97 049 147 dUTPase
HSPV043 44183-42744 (480) F3L 480 99 042 480 F3L 480 031L 476 046L 480 031 480 G3L 485 98 050 480 Kelch-like protein
HSPV044 45153-44197 (319) F4L 319 99 043 319 F4L 319 032L 319 049L 319 032 319 G4L 319 99 051 333 Ribonucleotide reductase small subunit
HSPV045 46150-45188 (321) F5L 321 96 044 322 F5L 322 033L 97 050L 321 033 321 G5L 323 95 052 323
034L 218
HSPV046 46404-46183 (74) F6L 74 100 045 74 F6L 74 035L 74 051L 74 034 74 G6L 74 100 053 71
HSPV047 46674-46423 (84) F7L 92 90 046 80 F7L 82 036L 80 052L 80 035 84 G7L 80 96 054 81
HSPV048 47035-46841 (65) F8L 65 93 047 65 F8L 50 037L 65 053L 65 036 65 G8L 65 98 055 65
HSPV049 47733-47098 (212) F9L 212 99 048 212 F9L 212 038L 212 054L 212 037 212 G9L 212 99 056 212
HSPV050 49039-47723 (439) F10L 439 99 049 439 F10L 439 039L 439 056L 439 038 439 G10L 439 99 057 439 Ser/Thr protein kinase
HSPV051 50126-49065 (354) F11L 354 99 050 348 F11L 354 040L 84 057L 354 039 354 G11L 354 99 059 354 RhoA-interacting protein
041L 100
HSPV052 52091-50187 (635) F12L 635 99 051 635 F12.1L* 635 042L 635 059L 635 040 635 G12L 634 97 060 634 IEV protein
HSPV053 53243-52128 (372) F13L 372 99 052 372 F13L 372 043L 372 060L 372 041 372 G13L 372 99 061 372 Palmitylated EEV envelope lipase
HSPV054 53482-53264 (73) F14L 73 98 053 73 F14L 73 044L 73 061L 73 042 73 G14L 73 97 062 73
HSPV055 54230-53757 (158) F15L 158 98 054 147 F15L* 158 045L 158 063L 158 043 158 G15L 158 99 064 158
HSPV056 54932-54240 (231) F16L 231 98 055 231 F16L 231 046L 231 064L 231 044 231 G16L 231 97 065 231
HSPV057 54995-55297 (101) F17R 101 98 056 101 F17R 101 047R 101 065R 101 045 101 G17R 101 99 066 101 DNA binding virion core protein
HSPV058 56736-55300 (479) E1L 479 99 057 479 E1L 479 048L 479 067L 479 046 479 F1L 479 98 067 479 Poly(A) polymerase large subunit
HSPV059 58946-56736 (737) E2L 737 99 058 737 E2L 737 049L 737 068L 737 047 737 F2L 737 97 068 737
HSPV060 59619-59050 (190) E3L 190 97 059 190 E3L* 190 050L 190 069L 190 048 190 F3L 190 97 069 190 dsRNA binding PKR inhibitor
HSPV061 60453-59677 (259) E4L 259 99 060 259 E5L 259 051L 259 070L 259 049 259 F4L 259 98 070 261 RNA polymerase subunit RPO30
HSPV062 60530-61522 (331) E5R 331 97 061 341 E6R 257 052R 331 071R 341 050 341 F5R 331 94 071 319
Right-terminal genomic region
HSPV146a 146239-146030 (70) A25L 65 91 145 65 A27L 233 136L 65 185L 210 233 A26L 1,279 67 158 1,284 ATI protein
HSPV146b 146819-146211 (203) A26L 322 93 146 154 A27L 233 185L 210 233 A26L 1,279 94 158 1,284
HSPV146c 147691-147167 (175) 147 227 A29L 230 187L 227 227 A26L 1,279 94 158 1,284
HSPV146d 149828-147654 (725) 148 725 A31L 725 189L 725 725 A26L 1,279 97 158 1,284
HSPV147 151378-149876 (501) A26L 322 98 149 500 A33L 168 137L 230 191L 502 134 500 A27L 518 94 159 192 IMV ATI-like protein P4c
A34L 71 161 260
A35L 229
HSPV148 151761-151432 (110) A27L 110 99 150 110 A36L 110 138L 110 192L 110 135 110 A28L 110 99 162 110 IMV membrane protein
HSPV149 152202-151765 (146) A28L 146 99 151 146 A37L* 146 139L 146 193L 146 136 146 A29L 146 99 163 146 IMV membrane protein
HSPV150 153120-152206 (305) A29L 305 99 152 305 A38L 305 140L 305 195L 305 137 305 A30L 305 98 164 305 RNA polymerase subunit RPO35
HSPV151 153316-153086 (77) A30L 77 100 153 77 A39L 77 141L 77 196L 77 138 77 A31L 77 100 165 76 Virion core protein
HSPV152 153476-153874 (133) A31R 124 90 154 124 A40R 141 142R 125 197R 127 139 124 A32R 145 90 166 140
HSPV153 154656-153847 (270) A32L 300 99 155 270 A41L 327 143L 269 199L 270 140 300 A33L 300 99 167 311 ATPase, DNA packaging
HSPV154 154774-155328 (185) A33R 185 100 156 185 A42R* 185 144R 185 200R 185 141 185 A34R 185 98 168 187 EEV envelope protein
HSPV155 155355-155858 (168) A34R 168 99 157 168 A44R 168 145R 168 201R 168 142 168 A35R 168 97 169 168 EEV envelope protein
HSPV156 155905-156432 (176) A35R 176 98 158 176 A45R 176 146R 176 202R 176 143 177 A36R 176 98 171 176
HSPV157 156502-157170 (223) A36R 221 99 159 221 A46R 221 147R 208 204R 221 144 224 A37R 223 98 172 224 IEV protein
HSPV158 157237-158025 (263) A37R 263 99 160 263 A47R 268 148R 263 205R 263 145 263 A38R 268 95 173 263
HSPV159 158139-158324 (62) 64 161 62 64 57 207R 62 56 A39R 64 95 174 63
HSPV160 159157-158327 (277) A38L 277 95 162 277 Unknown 277 149L 277 208L 277 146 277 A40L 277 97 175 277 CD47-like membrane glycoprotein
HSPV161 159173-160150 (326) A39R 403 93 163 295 A49R 228 150R 83 209R 403 147 401 A41R 402 94 176 409 Semaphorin-like protein
164 142 A50R 142 151R 210
HSPV162 160402-160896 (165) A40R 168 97 165 159 A51R 159 152R 168 211R 159 148 159 A42R 166 95 177 160 C-type lectin-like membrane protein
HSPV163 161656-161000 (219) A41L 219 97 166 219 A52L 219 153L 219 212L 219 149 219 A43L 219 97 178 218 Secreted immunomodulatory protein
HSPV164 161827-162225 (133) A42R 133 97 167 133 A53R 133 154R 128 213R 133 150 133 A44R 133 100 179 133 Profilin-like protein
HSPV165 162266-162850 (195) A43R 194 93 168 194 A54R 194 155R 190 214R 194 151 194 A45R 196 95 180 194
HSPV166 164226-163189 (346) A44L 346 98 170 346 A55L 346 157L 346 216L 346 153 346 A47L 346 98 182 346 Hydroxysteroid dehydrogenase
HSPV167 164273-164647 (125) A45R 125 99 171 125 A56R 125 158R 121 217R 125 154 125 A48R 125 98 183 125 Superoxide dismutase-like protein
HSPV168 164640-165359 (240) A46R 214 100 172 240 A57R 210 159R 240 218R 240 155 240 A49R 240 97 184 242 TLR/IL-1R signaling inhibitor
HSPV169 166183-165452 (244) A47L 244 99 173 252 A58L 252 160L 238 220L 252 156 244 A50L 244 97 185 244
HSPV170 166282-166893 (204) A48R 204 100 174 227 A59R 204 161R 204 221R 204 157 204 A51R 227 99 186 227 Thymidylate kinase
HSPV171 166944-167429 (162) A49R 162 96 175 162 A60R 162 162R 162 222R 162 158 162 A52R 162 95 187 162
HSPV172 167464-169119 (552) A50R 552 98 176 552 A61R 552 163R 552 223R 552 159 552 A53R 552 97 188 554 DNA ligase
HSPV173a 169175-169414 (80) A51R 334 88 177 334 A62R* 334 164R 310 226R 73 84 A54R 334 92 189 334
HSPV173b 169359-170168 (270) A51R 334 96 177 334 A62R 334 164R 310 227R 266 126 A54R 334 96 189 334
120
HSPV174 170241-170810 (190) A52R 190 98 178 190 A63R* 190 228R 190 160 190 A55R 190 96 190 190 TLR/IL-1R signaling inhibitor
HSPV175 171134-171439 (102) A53R 108 91 179 103 * 137 229R 186 161 102 A56R 186 88 191 186 TNFR, CrmC
AORFT 81 100 * 103
HSPV176 171969-173660 (564) A55R 564 99 180 564 A65R* 564 232R 564 162 564 A57R 564 97 193 563 Kelch-like protein
HSPV177 173713-174654 (314) A56R 315 98 181 314 A66R 315 165R 315 233R 310 163 206 A58R 314 94 194 297 EEV hemagglutinin
HSPV178a 174675-174860 (62) A57R 151 93 182 151 A67R 151 234R 37 164 151 A59R 197 96 195 197 Guanylate kinase
HSPV178b 174975-175265 (97) A57R 151 100 182 151 A67R 151 166R 97 235R 151 164 151 A59R 197 95 195 197
HSPV179 175419-176318 (300) B1R 300 99 183 300 B1R 300 167R 300 236R 300 165 300 B1R 300 99 196 299 Ser/Thr protein kinase, DNA replication
HSPV180a 176412-177068 (219) B2R 219 96 184 219 B2R 219 168R 96 238R 219 219 B2R 503 93 197 505
169R 143
HSPV180b 177107-177478 (124) B3R 124 96 185 167 B3R 124 170R 179 240R 124 124 B2R 503 91 197 505 Schlafen-like protein
HSPV181 178138-179811 (558) B4R 558 98 186 558 B4R 558 171R 177 242R 558 166 558 B3R 558 95 198 558 Ankyrin repeat protein
172R 409
HSPV182 179917-180867 (317) B5R 317 97 187 317 B5R 317 173R 317 243R 317 167 317 B4R 317 96 199 317 EEV host range protein
HSPV183a 180953-181285 (111) B6R 173 99 188 173 B6R 173 174R 173 244R 173 168 173 B5R 183 93 200 179
HSPV183b 181288-181482 (65) B6R 173 100 188 173 B6R 173 174R 173 244R 173 168 173 B5R 183 93 200 179
HSPV184 181523-182068 (182) B7R 182 100 189 182 B7R 182 175R 177 246R 182 169 182 B6R 182 97 201 181 Chemokine binding domain
HSPV185 182149-182964 (272) B8R 272 97 190 272 B8R 272 176R 226 247R 272 170 272 B7R 271 97 202 266 IFN-γ receptor
HSPV186 183054-183284 (77) B9R 77 100 191 77 B9R 77 177R 72 248R 77 61 B8R 221 97 203 225 MYXV M-T4-like protein
HSPV187 183384-183746 (121) B10R 166 99 192 166 B10R 166 178R 158 249R 166 172 166 B9R 501 94 204 501 Kelch-like protein
HSPV188 183821-184054 (78) B11R 88 96 193 72 B11R 76 179R 74 250R 72 173 72 B10R 105 96 205 90
HSPV189 184124-184972 (283) B12R 283 98 194 283 B12R 283 180R 283 251R 283 174 283 B11R 283 98 206 285 Ser/Thr protein kinase
HSPV190 185074-186108 (345) B14R 222 97 195 345 B14R 222 181R 116 253R 222 175 345 B12R 345 93 207 341 Serpin, SPI-2
182R 222
HSPV191 186186-186632 (149) B15R 149 97 196 149 B15R 149 183R 143 254R 149 176 149 B13R 149 98 208 149
HSPV192 186736-187713 (326) B16R 290 97 197 326 B16R 290 184R 326 255R 326 207 B14R 326 95 209 326 IL-1 receptor
134
HSPV193 188784-187765 (340) B17L 340 97 198 340 B17L 340 185L 340 257L 340 177 340 B15L 340 96 210 340
HSPV194 188921-190642 (574) B18R 574 98 199 574 B18R 574 186R 574 258R 413 178 574 B16R 574 95 211 574 Ankyrin repeat protein
HSPV195 190711-191775 (355) B19R 353 98 200 351 B19R 353 187R 234 179 351 B17R 351 91 212 366 IFN-α/β binding protein
HSPV196 191850-194222 (791) B20R 127 96 202 53 B20R* 613 180 791 B18R 795 94 213 800 Ankyrin repeat protein
203 309
HSPV197 194331-195971 (547) 204 134 B19R 557 94 215 557 Kelch-like protein
HSPV198 196272-197342 (357) C12L 353 97 205 353 C19L 353 004L 353 005 357 B20R 375 95 217 372 Serpin, SPI-1
HSPV199 197515-198090 (192) C13L 65 90 206 190 003L 190 004 192 B21R 190 94 218 198 Chemokine binding domain protein
C14L 82 98
HSPV200 198347-204106 (1,920) 188R 70 B22R 1,033 97 219 1,019 VARV B22R-like protein
HSPV201a 204447-204806 (120) B21R 91 96 002L 89 003 91 K1R 581 96 220 579 Ankyrin repeat protein
HSPV201b 204961-205161 (67) 189R 188 K1R 581 90 220 579
HSPV202 205215-205673 (153) B22R 181 97 189R 188 L01L 147 002 184 I1R 153 97 222 153
HSPV203a 205837-207027 (397) B23R 386 92 190R 233 L02L 416 385 I2R 672 94 223 672 Ankyrin repeat protein
191R 102
HSPV203b 207104-207553 (150) B24R 150 98 L03L 98 163 I2R 672 92 223 672
HSPV203c 207583-207855 (91) L03L 93 I2R 672 97 223 672
HSPV204 208064-209824 (587) B25R 259 90 211 112 L04L 100 140 I3R 586 95 225 619 Ankyrin repeat protein
B26R 103 69 212 109 L06L 128 77
B27R 113 100 213 64 L07L 48 109
214 48 113
HSPV205 209912-210958 (349) B28R 122 91 215 122 192R 176 L08L 122 122 I4R 351 95 226 355 TNFR II-like protein, CrmB
217 61 L09L 34 63
HSPV206 211087-211830 (248) B29R 244 86 218 244 B23R 244 193R 136 L10L 258 001 258 I5R 255 87 227 246 Chemokine binding protein
HSPV207 211946-212161 (72) 229 64
a

Boldface indicates ORFs >10% different in length from intact orthologues from CPXV GRI-90 or BRI. Names of ORF homologues have been abbreviated here for simplicity and lack the following prefixes for the following viruses: VACV WR, WR; T, Tian Tan; MVA, MVA; m0LTR, ORFs in the m0 long terminal repeat indicated here with prefix L; m0, unique m0 ORFs; RPXV, RPXV; CPXV, BRI.

b

All lengths are in amino acids.

c

VACV strains (accession numbers): CPN (M35027); WR (AY243312); Tian, Tian Tan (AF095689); MVA (U94848); m0, LC16m0 (AY678277). Larger ORFs matching multiple HSPV ORFs are VACV CPN ORFs C5L, C4L, M1L, A26L, A51R, A57R, and B6R; VACV WR ORFs 014, 023, 024, 030, 177, 182, and 188; VACV Tian Tan ORFs C5L, C4L, M1L, A27L, A62R, A67R, and B6R; VACV MVA ORFs 164R, 174R, and 189R; and VACV m0 ORFs L03L, 022L, 023L, 030L, 185L, and 244R.

d

RPXV strain Utrecht. RPXV ORF lengths lacking an ORF designation indicate ORFs lacking translation products annotated in sequence AY484669. Larger ORFs matching multiple HSPV ORFs are the 409-amino-acid-long ORF, ORF 015, ORF 016, ORF 022, the 233-amino-acid-long ORF, ORF 164, and ORF 168.

e

CPXV strains (accession numbers): GRI, GRI-90 (X94355); BRI (AF482758). Larger ORFs matching multiple HSPV ORFs are GRI-90 ORFs D4L, D14L, C3L, C4L, C9L, C15L, C16L, P1L, A26L, A54R, A59R, B2R, B5R, K1R, and 12R and BRI ORFs 008, 016, 019, 020, 025, 033, 039, 158, 189, 195, 197, 200, 220, and 223.

f

% Id, percent amino acid identity in local BLAST match.

g

Asterisks indicate ORFs resequenced/reannotated by Upton et al. (92) as present, intact, or fused to a subsequent ORF in the Tian Tan genome.

h

Abbreviations: IL-18, interleukin-18; TLR, Toll-like receptor; PKR, double-stranded RNA-dependent protein kinase; IEV, intracellular enveloped virion; IFN-γ, gamma interferon; MYXV, myxoma virus; dsRNA, double-stranded RNA.

TABLE 2.

HSPV ORFs in central genomic regions compared to orthologues annotated in VACV CPNaa

HSPV ORF Position (lengthc) VACV CPN
Putative function/similarity
ORF Length
HSPV063 61662-63362 (567) E6R 567
HSPV064 63447-63944 (166) E7R 166
HSPV065 64072-64890 (273) E8R 273 Virion core protein
HSPV066 67919-64902 (1,006) E9L 1,006 DNA polymerase
HSPV067 67951-68235 (95) E10R 96 IMV redox protein
HSPV068 68622-68236 (129) E11L 129 Virion core protein
HSPV069 70609-68612 (666) O1L 666
HSPV070 70983-70660 (108) O2L 108 Glutaredoxin
HSPV071 72067-71132 (312) I1L 312 DNA binding virion core protein
HSPV072 72304-72077 (76) I2L 73
HSPV073 73114-72308 (269) I3L 269 DNA binding phosphoprotein
HSPV074a 73439-73200 (80) I4Lb 771 Ribonucleotide reductase large subunit
HSPV074b 74885-73566 (440) I4L 771
HSPV074c 75213-74842 (124) I4L 771
HSPV074d 75503-75216 (96) I4L 771
HSPV075 75770-75534 (79) I5L 79 IMV membrane protein
HSPV076 76937-75792 (382) I6L 382 Telomere binding protein
HSPV077 78201-76933 (423) I7L 423 Virion core proteinase
HSPV078 78207-80234 (676) I8R 676 RNA helicase NPH-II
HSPV079 82016-80244 (591) G1L 591 Metalloprotease
HSPV080 82342-83001 (220) G3L 220
HSPV081 82348-82016 (111) G2R 111 Transcriptional elongation factor
HSPV082 83348-82977 (124) G4L 124 Glutaredoxin 2
HSPV083 83351-84652 (434) G5R 434 Virion core protein
HSPV084 84663-84851 (63) G5.5R 63 RNA polymerase subunit RPO7
HSPV085 84856-85350 (165) G6R 166
HSPV086 86433-85321 (371) G7L 371 Virion core protein
HSPV087 86464-87243 (260) G8R 260 Late transcription factor VLTF-1
HSPV088 87266-88285 (340) G9R 340 Myristylated protein
HSPV089 88289-89038 (250) L1R 250 Myristylated IMV envelope protein
HSPV090 89073-89333 (87) L2R 87
HSPV091 90378-89329 (350) L3L 350
HSPV092 90403-91155 (251) L4R 251 DNA binding virion core protein
HSPV093 91168-91551 (128) L5R 128 IMV membrane protein
HSPV094 91511-91969 (153) J1R 153 IMV membrane protein
HSPV095 91988-92518 (177) J2R 177 Thymidine kinase
HSPV096 92587-93585 (333) J3R 333 Poly(A) polymerase small subunit
HSPV097 93503-94057 (185) J4R 185 RNA polymerase subunit RPO22
HSPV098 94585-94187 (133) J5L 133
HSPV099 94692-98549 (1,286) J6R 1,286 RNA polymerase subunit RPO147
HSPV100 99064-98552 (171) H1L 171 Tyr/Ser protein phosphatase
HSPV101 99078-99644 (189) H2R 189 IMV membrane protein
HSPV102 100624-99653 (324) H3L 324 IMV envelope protein
HSPV103 103012-100628 (795) H4L 795 RNA polymerase-associated protein
HSPV104 103198-103830 (211) H5R 203 Late transcription factor VLTF-4
HSPV105 103834-104775 (314) H6R 314 DNA topoisomerase IB
HSPV106 104815-105252 (146) H7R 146
HSPV107 105299-107830 (844) D1R 844 mRNA capping enzyme large subunit
HSPV108 108225-108935 (237) D3R 237 Virion core protein
HSPV109 108232-107795 (146) D2L 146 Virion core protein
HSPV110 108938-109591 (218) D4R 218 Uracil DNA glycosylase
HSPV111 109626-111980 (785) D5R 785 NTPase, DNA replication
HSPV112 112024-113934 (637) D6R 637 Early transcription factor small subunit
HSPV113 113964-114446 (161) D7R 161 RNA polymerase subunit RPO18
HSPV114 115326-114415 (304) D8L 304 IMV membrane protein, cell binding
HSPV115 115368-116006 (213) D9R 213 MutT motif
HSPV116 116006-116749 (248) D10R 248 MutT motif
HSPV117 118648-116756 (631) D11L 631 NPH-I, transcription termination factor
HSPV118 119546-118686 (287) D12L 287 mRNA capping enzyme small subunit
HSPV119 121232-119580 (551) D13L 551 Rifampin resistance protein
HSPV120 121708-121259 (150) A1L 150 Late transcription factor VLTF-2
HSPV121 122403-121732 (224) A2L 224 Late transcription factor VLTF-3
HSPV122 122630-122403 (76) A2.5L 76 Virion redox protein
HSPV123 124579-122648 (644) A3L 644 Virion core protein P4b
HSPV124 125477-124635 (281) A4L 281 Virion core protein
HSPV125 125515-126006 (164) A5R 164 RNA polymerase subunit RPO19
HSPV126 127124-126009 (372) A6L 372
HSPV127 129280-127151 (710) A7L 710 Early transcription factor large subunit
HSPV128 129334-130197 (288) A8R 288 Intermediate transcription factor VITF-3
HSPV129 130501-130196 (102) A9L 99 IMV membrane protein
HSPV130 133177-130505 (891) A10L 891 Virion core protein P4a
HSPV131 133192-134145 (318) A11R 318 Nonstructural protein
HSPV132 134725-134153 (191) A12L 192 Virion core protein
HSPV133 134961-134752 (70) A13L 70 IMV membrane protein
HSPV134 135341-135072 (90) A14L 90 IMV membrane protein
HSPV135 135519-135361 (53) A14.5L 53 IMV membrane protein
HSPV136 135793-135512 (94) A15L 94 Virion core protein
HSPV137 136913-135780 (378) A16L 378 Myristylated IMV membrane protein
HSPV138 137527-136919 (203) A17L 203 Phosphorylated IMV membrane protein
HSPV139 137542-139020 (493) A18R 493 DNA helicase, transcriptional elongation
HSPV140 139237-139007 (77) A19L 77
HSPV141 139590-140867 (426) A21L 426 DNA polymerase processivity factor
HSPV142 139591-139241 (117) A20R 117 IMV membrane protein
HSPV143 140833-141360 (176) A22R 176 Holliday junction resolvase
HSPV144 141383-142528 (382) A23R 382 Intermediate transcription factor VITF-3
HSPV145 142528-146019 (1,164) A24R 1,164 RNA polymerase subunit RPO132
a

Boldface indicates ORFs >10% different in length from intact orthologues from CPXV GRI-90 or Brighton Red.

b

I4L is a larger ORF matching multiple HSPV ORFs.

c

Lengths are in amino acids.

HSPV contained 236 ORFs potentially encoding proteins of 53 to 1,920 amino acids and sharing similarity with those in previously described OPV genomes (Tables 1 and 2). Of these 236 annotated ORFs, 54 were significantly smaller or fragmented forms of 25 larger ORFs present in other OPVs, leaving 182 potentially full-length OPV gene homologues. The HSPV central genomic region contained genes colinear and highly conserved among other OPV genomes, with ORFs HSPV041 to HSPV145 sharing an average 98% amino acid identity with VACV CPN ORFs F1L to A24R and with CPXV GRI-90 ORFs G1L to A25R (Table 2 and data not shown). Genes in this conserved region included those involved in basic replicative functions such as viral transcription and transcript modification, DNA replication, and assembly of intracellular mature and extracellular enveloped virions (IMVs and EEVs, respectively), indicating that HSPV is similar to other OPVs in these functions (59) (Table 2).

HSPV terminal genomic regions were similar to other OPVs in that they contained a homologous subset of the sequence and intact ORFs present in various strains of CPXV, viruses found to contain a relatively complete OPV genotype and thus thought to be viruses from which other OPV lineages are derived following gene fragmentation and loss (Table 1; Fig. 1) (75, 79). Many of these ORFs have been characterized in other OPVs as affecting viral virulence, host range, and modification of host responses, including apoptosis and innate and adaptive immune mechanisms (59, 60, 82). However, the specific subset of genes present in HSPV was unique relative to other OPVs, containing terminal genomic sequences not characteristic of currently known OPVs and including approximately 1.4 kb of sequence found only in CPXV (located between positions 15453 and 16985) (Fig. 1).

FIG. 1.

FIG. 1.

FIG. 1.

Schematic comparison of HSPV left (A) and right (B and C) terminal genomic regions to those of other orthopoxviruses. Virus names were abbreviated as follows and correspond to sequences from the following GenBank accession numbers in parentheses: VACV CPN (M35027); VACV WR (AY243312); Tian, VACV Tian Tan (AF095689); VACV MVA (U94848); m0, VACV Lister isolate LC16m0 (AY678277); RPXV, RPXV Utrecht (AY484669); GRI, CPXV GRI-90 (X94355); MPXV, MPXV Zaire-96-I-16 (AF380138); ECTV, ECTV Moscow (AF012825); CMLV, CMLV M-96 (AF438165); VARV, VARV Bangladesh-1975 (L22579); CPXV BRI (AF482758). Heavy lines indicate nucleotide sequences; boxes indicate ORFs matching those annotated in HSPV and those in genomic regions absent in HSPV. ORF names and genomic positions in kilobase pairs (K) are indicated for HSPV and CPXV Brighton Red, as are names of ORFs absent in these two species. Hatching indicates ORFs different in length (>10%) from intact orthologues from CPXV GRI-90 or Brighton Red. Red ORFs indicate HSPV ORFs intact or carried on sequences that are absent relative to VACV-like viruses. Asterisks indicate ORFs resequenced/reannotated by Upton et al. (92) as present or intact in the Tian Tan genome. Large solid-lined boxes indicate sequences matching the global alignment only at the opposite genomic terminus; dashed boxes indicate where sequences located in the opposite genomic terminus match the global alignment. Red lines indicate ITR sequence in each virus and are unaligned on the terminal side of HSPV002/HPSV206. Panel A is presented at a different scale relative to panels B and C.

Phylogenetic analysis.

Phylogenetic analysis of OPV genomic regions, including the highly conserved central region and parts of the more variable terminal regions, indicated that HSPV is closely related to sequenced strains of VACV and RPXV, falling very close to or within this VACV subgroup (referred to here as VACV-like viruses) relative to other OPVs (Fig. 2). These results are consistent with those obtained previously for OPVs, with VACV-like viruses closely related to each other compared to other OPV species, and they indicated that HSPV is a VACV-like virus (21, 38, 51). As a VACV-like virus, HSPV also shares a closer relationship with CPXV strain GRI-90 than with CPXV strain Brighton Red (BRI), consistent with previous OPV phylogenetic analyses and indicating the distinct nature of CPXV species despite the relative conservation in gene content (Fig. 1 and 2) (21, 38, 51). Similarly, a close relationship was observed between HSPV and VACV using concatenated right terminal OPV gene sequences used previously for OPV phylogenetic analysis (HSPV177, HSPV179, HSPV182, and HSPV191; data not shown) (38). These results indicate that HSPV and VACV are very similar phylogenetically and share a relatively recent common ancestor. Notably, HSPV had a slightly greater estimated distance to VACV-like isolates than they demonstrated to each other, with HSPV tending to fall outside the rest of the VACV-like cluster (Fig. 2). These data suggested that, while very closely related, HSPV is phylogenetically distinct from other characterized VACV-like viruses.

FIG. 2.

FIG. 2.

Phylogenetic analysis of HSPV central genomic regions. Conserved HSPV central genomic nucleotide sequences (positions 26800 to 170171) corresponding to regions used previously for OPV phylogenetic analysis (51) were aligned with homologous OPV sequences using DIALIGN, and gapped regions were realigned with CLUSTAL W and trimmed with Gblocks. The unrooted tree for 124,677 aligned characters was generated using maximum likelihood with general time reversible correction for multiple substitutions, four-category discrete gamma model, estimation for proportion of invariant residues, and 100 bootstrap replicates as implemented in PHYML. Bootstrap values greater than 70 are indicated at appropriate nodes; dots indicate values of 100. Homologous nucleotide sequences from the following viruses and accession numbers were compared: VACV strain CPN, M35027; VACV WR, AY243312; VACV Lister (Elstree) vaccine consensus (Lis), AY678276; VACV Lister-derived LC16m0 (m0), AY678277; VACV Tian Tan (Tian), AF095689; VACV MVA, U94848; RPXV Utrecht (RPXV), AY484669; CPXV strain GRI-90 (X94355); CPXV BRI, AF482758; MPXV strain Zaire-96-I-16 (MPXV ZAI), AF380138; MPXV WRAIR7-61 (MPXV W61), AY603973; MPXV USA_2003_039 (MPXV U39), DQ011157; CMLV strain M-96 (CMLV M96), AF438165; CMLV CMS, AY009089; VARV strain Bangladesh-1975 (VARV BAN), L22579; VARV India-1967 (VARV IND), X69198; VARV Garcia-1966 (VARV GAR); Y16780; ECTV strain Moscow (ECTV MOS), AF012825. The scale indicates estimated distance. Identical topologies at supported nodes were obtained using additional maximum likelihood analyses as implemented in TREE-PUZZLE, using neighbor-joining and maximum parsimony as implemented in PHYLO_WIN and PHYLIP, respectively, and using an unedited alignment (146,439 characters) (data not shown). Similar topologies were also obtained using similar analyses on whole-genomic alignments (data not shown).

Comparison of HSPV with VACV-like viruses.

Given the close phylogenetic relationship between HSPV and VACV-like viruses, HSPV ORFs were compared to VACV-like homologues in the more variable terminal genomic regions which tend to contain genes dispensable for basic replicative processes but important for specific virus-host interaction and aspects of virulence and host range (Fig. 1; Table 1). While HSPV maintained a high level of amino acid identity where homologous terminal region ORFs were present (average of 95% amino acid identity to CPN), we focused here on comparison of HSPV and VACV in genes likely fragmented relative to CPXV and other OPVs. Overall, these differences often involved genes that are members of multigene families and/or homologues of genes shown or thought to affect OPV virulence or host range, among them those that code for ankyrin repeat proteins, kelch-like proteins, and tumor necrosis factor receptors (TNFRs) (4, 45, 77). While terminal-region genotypes vary both among OPVs and between known VACV-like viruses, HSPV contained features similar to known VACV-like viruses relative to other OPVs and features that were quite novel (Table 1; Fig. 1).

HSPV genetic features similar to VACV.

Genotypic similarity between HSPV and other VACV-like viruses included a number of genes that were fragmented relative to CPXV and occasionally relative to other OPVs. These genes included several which were fragmented or arranged in a similar fashion between HSPV and VACV-like viruses, commensurate with their close phylogenetic relationship (Table 1; Fig. 2). HSPV genes sharing similar ORF fragments with those in certain VACVs include HSPV005/HSPV203 and HSPV020, genes encoding ankyrin proteins and fragmented or missing in most OPVs (Fig. 1A). HSPV005b/HSPV203b in the ITR represents the same fragment of GRI-90 D4L/I2R as CPN C18L/B24R. HSPV020a to -e and similar ORFs in VACV are homologous fragments of CPXV CHOhr, a gene which enables replication of VACV in the normally nonpermissive CHO cell line and affects eukaryotic initiation factor 2α (eIF2α) phosphorylation in HeLa cells (41, 85). Other HSPV ORFs with similar VACV fragments included HSPV146d, HSPV180, and HSPV186. HSPV146d encodes the same 725-amino-acid amino-terminal fragment of the A-type inclusion (ATI) protein present in several VACV-like viruses and expressed in some as a soluble 94-kDa protein (26). HSPV186 is a VACV-like ORF fragment homologous to the amino-terminal region of the OPV homologue of myxoma virus M-T4, a protein important for virulence and infection of lymphocytes by myxoma virus (12). The HSPV186 homologue is expressed in VACV strain Western Reserve (WR); however, deletion mutants were not affected for viral growth in vitro or virulence in mice (68). While amino-terminal M-T4-like fragments are also present in certain strains of MPXV (22, 52), the large nucleotide deletion affecting HSPV186 was characteristic of VACV (Fig. 1C). Also characteristic of VACV are homologues of HSPV180a and HSPV180b (CPN B2R and B3R, respectively), apparent fragments of a larger ORF intact in all OPV species other than VACV and VARV and previously annotated as similar to cellular Schlafen, a family of variably sized proteins with the prototypical 337-amino-acid murine Schlafen 1 recently shown to target cyclin D1 pathways during induction of cellular mid-G1 cell cycle arrest (15, 39). Notably, HSPV180a and HSPV180b revealed the bipartite nature of the larger OPV homologue, with Schlafen similarity present in the HSPV180b-like (carboxyl-terminal) region and the HSPV180a-like (amino-terminal) region sharing similarity with the putative B2R homologue of Melanoplus sanquinipes entomopoxvirus (MSV237) and limited similarity with ORFs of unknown function (p26) from nucleopolyhedrosis viruses (data not shown). While maintenance of these two domains as separate ORFs in HSPV and VACV conceivably suggests function, HSPV180b and VACV orthologues lack carboxyl-terminal sequences both present in the intact OPV ORF and similar to the carboxyl terminus of cellular Schlafen. Overall, similar fragmentation patterns between HSPV and VACV potentially represent shared, derived characters.

Several genes fragmented in HSPV were also fragmented in certain VACV-like isolates but intact in others (Table 1). HSPV ORF fragments with intact homologues in certain VACVs included HSPV018, HSPV161, HSPV173a and -b, and HSPV175. HSPV018 is an amino-terminal fragment homologue of the ECTV p28 ubiquitin ligase, a protein critical for ECTV virulence and macrophage host range and having intact homologues in all other OPV species (74, 87) (Fig. 1). While this gene is also fragmented in several VACV strains, intact homologues have been identified in VACV strains IHD-W and Lister and in RPXV (51, 58, 91). Similarly, HSPV173a and -b resembled homologous ORFs in VACV Lister and RPXV and fragments of the CPN A51R gene intact in other VACV strains and all other OPVs. HSPV161 was a homologue of CPN A39R, a secreted semaphorin affecting viral virulence and host inflammatory responses during infection, but, similarly to homologues in WR and other VACV strains, contained a carboxyl-terminal truncation that may predict a nonfunctional product (35). HSPV175, similar to several VACV-like viruses, encoded a truncated copy of the intact CrmC TNFR-like protein encoded by VACV strains Lister, Evans, and USSR (5). HSPV039 and HSPV187 were fragmented genes with homologues fragmented in all VACV-like viruses but with VACV-like homologues fragmented in a pattern distinct from those in HSPV. HSPV039 was similar to both CPN K5L and K6L fragments of the OPV monoglyceride lipase-like gene but was much closer in size to the intact CPXV homologue, and HSPV187 was a smaller fragment of the CPXV GRI-90 B9R kelch-like protein. While HSPV175, HSPV039, and HSPV187 homologues were fragmented in both HSPV and most VACV-like viruses, these genes were also disrupted in most other OPVs (Fig. 1).

HSPV also contained intact genes whose homologues were intact in certain VACV-like viruses but disrupted in others, similar to genes recently described in the RPXV genome (Table 1) (51). HSPV002/HSPV206 in the ITR encoded the OPV 35-kDa secreted chemokine binding protein and, similarly to the functional, full-length protein expressed by VACV Lister and other OPVs, lacked the amino-terminal mutation preventing expression of functional protein in CPN, WR, and VACV strain Tian Tan (6). HSPV147 was an intact copy of the gene encoding P4c, a protein involved with direction of IMV to insoluble ATIs but with homologues fragmented or absent in CPN, Tian Tan, and modified vaccinia Ankara (MVA). HSPV190 was only the third intact VACV-like orthologue of the serine proteinase inhibitor (serpin) 2 (SPI-2) to be identified, and HSPV198 was an intact orthologue of the SPI-1 gene intact in most VACV-like viruses but transposed to the opposite terminus in RPXV and VACV CPN, Tian Tan, and Lister and absent in MVA (Fig. 1C). Intact SPI-1 and SPI-2 exhibit antiapoptotic and/or anti-inflammatory activity through inhibition of caspases and have been shown to affect viral virulence and/or host range (48, 59, 82, 87). HSPV196 encodes an intact ankyrin repeat protein truncated by deletion in all VACV-like viruses except RPXV, where the homologue was recently identified as unique among VACV-like viruses in that the entire nucleotide region encompassing the gene was present (51). Similarly, HSPV199 encodes an intact homologue of the BRI CPXV218 chemokine binding protein, with intact homologues also encoded in the right terminus of WR and in the left terminus of VACV Lister and RPXV (Fig. 1) (7). Overall, different fragmentation patterns or gene loss between HSPV genes and VACV homologues may indicate sequence divergence after functional gene loss or, alternatively, could conceivably reflect independent loss of gene function in different VACV-like lineages during convergent adaptation toward similar virulence or host range phenotypes. Gene loss near ITR boundaries may reflect loss during terminal transposition events (47, 61). These phenomena would help explain gene fragmentation that is variable both within the VACV-like lineage and between OPV species.

HSPV genetic features distinct from VACV.

Despite sharing specific genomic and genotypic features with some or all known VACV-like viruses within the range of VACV-like genotypic heterogeneity, HSPV contained many features that were unique. These included genes uniquely intact in HSPV but for which homologous nucleotide sequence was present in other VACVs, and they included HSPV genes, both intact and fragmented, that were associated with nucleotide sequences completely novel among VACV-like viruses, resulting in terminal genomic regions encoding additional proteins and protein fragments resembling those in CPXV (94% average amino acid identity to CPXV GRI-90 orthologues) (Fig. 1; Table 1). Finally, HSPV demonstrated unique fragmentation of several genes, including those that were intact in all or most other known VACV-like viruses.

HSPV contained in the ITRs intact genes that are fragmented or absent in all other VACVs (Table 1). HSPV003/HSPV205 is an intact homologue of the secreted CPXV Brighton Red CrmB TNFR II-like protein (CPXV GRI-90 D2L/I2R), a protein which interacts with and inhibits TNF and lymphotoxin alpha and whose orthologue in VARV has been recently shown to contain a novel carboxyl-terminal chemokine binding domain also present and active in several other OPV proteins (4, 7, 42). HSPV004/HSPV204 encodes an intact homologue of the ankyrin repeat protein encoded by CPXV GRI D3L/I3R and intact homologues in MPXV, ECTV, and CMLV (Fig. 1).

HSPV contains approximately 17 kbp of sequence in three distinct genomic regions (positions 7527 to 18195 in the left terminal region and 194379 to 195517 and 198775 to 204285 in the right terminal region) absent in known VACV-like viruses but homologous to sequences in sequenced strains of CPXV and other OPVs (Fig. 1). HSPV also contains approximately 1.4 kbp of sequence absent not only in VACV but also in all known OPVs except CPXV. For this region, located between positions 15453 and 16985, only MPXV contains a fragment (approximately 75 bp) of homologous sequence. Notably, sequences near this region reflect ITR and/or terminal translocations in several OPVs (Fig. 1), and repetitive sequence near this locus in ECTV has been suggested to be a dynamic genomic region (21). Conceivably, the presence of this 1.4-kbp sequence in HSPV is consistent with retention of adjacent and relatively significant amounts of CPXV-like sequence in this left terminal region relative to other OPVs (Fig. 1).

HSPV sequence in the left terminal region absent in other VACV-like viruses corresponds to the D7L loci of CPXV GRI-90 and the CPXV014 to CPXV020 region of CPXV BRI (Fig. 1A). These sequences relative to other VACV-like viruses essentially extend from the ITR boundary region to the region upstream of the HSPV016 viral growth factor homologue (CPN C11R), replacing the OPV-like sequence that is transposed from the right terminal region to the left terminal region in other VACV-like viruses. HSPV sequences in this region include 15 ORFs representing three intact OPV genes (HSPV008, HSPV010, and HSPV012) and six potentially truncated or fragmented genes (HSPV007, HSPV009, HSPV011a to -c, HSPV013, HSPV014a to -d, and HSPV015a and -b) (Table 1; Fig. 1). HSPV008 encodes an intact protein orthologous only to CPXV GRI-90 D7L and ECTV strain Moscow EVM004 (21, 79). These proteins contain amino-terminal BTB/POZ domains, evolutionarily conserved domains important for oligomerization and ordering of protein complexes and often present in amino-terminal regions of both cellular and poxviral kelch-like proteins, but in these smaller HSPV008 orthologues the BTB/POZ domain is not associated with kelch repeat domains (3, 75). HSPV009 encodes a truncated orthologue of CPXV GRI-90 D12L product, a protein similar to the CrmB carboxyl terminus and whose orthologue in ECTV was recently characterized as a secreted chemokine binding protein (7). HSPV010 encodes an intact orthologue of CD30 TNFR-like proteins present in CPXV and ECTV, proteins able to bind CD30 ligands and/or have immunomodulatory effects (63, 72). HSPV left-end sequences also contain genes for three ankyrin repeat proteins absent in VACV. While HSPV012 encodes an intact ankyrin repeat protein also intact in CPXV and MPXV, HSPV011a to -c and HSPV014a to -d encode fragments of intact ankyrin repeat proteins encoded only in ECTV and/or CPXV, with HSPV014b and -c encoded within the region containing 1.4 kbp of sequence found only in CPXV. Finally, HSPV015a and -b appeared to encode fragments of a paralogue of CPN C7L, a VACV host range protein which enables viral replication in human cells (67). While all OPVs appear to encode intact C7L orthologues (HSPV024), intact HSPV015 orthologues are encoded only in CPXV and CMLV, with fragmented ORFs annotated in MPXV and VARV (Table 1).

HSPV sequence in the right terminal region absent in other VACV-like viruses essentially bound the region homologous to the VACV WR SPI-1 (HSPV198) locus, a region transposed to the opposite terminus in several other VACVs (Fig. 1). Unique sequence upstream of HSPV198 includes HSPV197, an intact kelch-like protein also intact in CPXV and ECTV but fragmented or absent in MPXV, CMLV, and VARV. Unique sequences downstream of HSPV198 contain an intact orthologue of the VARV strain Bangladesh B22R gene (HSPV200). B22R homologues represent the largest poxviral genes, encoding proteins of approximately 2,000 amino acids and with no known function but predicted to contain carboxyl-terminal transmembrane domains and cysteine residues which conceivably mediate disulfide bond formation (54, 56, 76). B22R homologues are intact in all OPV species except VACV-like viruses, making the presence of HSPV200 notable (Fig. 1).

Despite containing additional sequence not present in other VACV-like viruses, HSPV did lack sequences homologous to several larger regions in other OPVs. These include from GRI-90 the D8L to D11L locus, a region encoding ankyrin repeat, kelch-like, and lectin-like proteins with homologous sequence only in ECTV (79) (Table 1), and most of the K1R to S1R/T1R locus, a region encoding ankyrin repeat, CrmD TNFR, and CrmE TNFR proteins and with homologous sequence present in MPXV, ECTV, and CMLV and, notably, in VACV Lister (Fig. 1C). HSPV also lacks any remnant of the second VARV B22R-like gene identified in certain strains of CPXV and of which remnants remain in VARV and CMLV lineages (HSPV185-HSPV186 locus [Fig. 1C]) (56).

Finally, HSPV contains fragmented genes intact in all or nearly all other VACV-like viruses. Within the central conserved region, HSPV074a to -d represented fragments of the CPN I4L ribonucleotide reductase large subunit gene, while HSPV044 encoded an intact small subunit (Table 2). Ribonucleotide reductase is a heterodimeric protein involved in redox reactions that are key to synthesis of deoxyribonucleotides, an activity for which various poxviruses encode different enzyme complements, potentially adapted to replication in specific host cell types lacking adequate nucleotide pools (59). Experimental disruption of the VACV ribonucleotide reductase large subunit has been shown previously to have no effect on virus replication in vitro and a mild effect on virulence in mice (23). Although I4L homologues are not encoded in all other poxviral genera, to our knowledge this is the first example of its natural disruption in an OPV genome. Similarly, HSPV183 is unique among VACV-like homologues (CPN B6R) as the only form of the gene to be fragmented, although a fragmented form is also found in VARV (Fig. 1B) and an isolate of MPXV (accession no. AAY97373). Notably, HSPV contained fragmented genes intact in all VACVs except MVA, a virus that has accumulated numerous mutations and extensive nucleotide deletions through extensive passage in vitro and concomitant attenuation and restriction of host range (9). These include HSPV026, orthologue of CPN C5L BTB domain protein, and the HSPV033 ankyrin repeat protein. In addition, HSPV178, similar to MVA, demonstrates a smaller fragmented form of the guanylate kinase gene than do other VACV-like viruses.

Perspective on relationship of HSPV to VACV.

Genomic sequence analysis of HSPV MNR-76 indicates that it is a novel VACV-like OPV that contains unique features not present in known VACVs. Although MNR-76 is unique in the complement of OPV genes remaining intact in HSPV, the pattern of terminal gene loss/fragmentation is commensurate with genotypes observed in other VACV-like viruses. Notably, the majority of left terminal HSPV sequence absent in VACV appears to contain gene fragments, with HSPV conceivably in the process of losing this sequence similarly to other VACV-like viruses.

The close phylogenetic and genotypic relationship between HSPV and other VACV-like viruses and the presence of additional CPXV-like sequences in HSPV are notable given previous speculations involving horsepox and the origins of VACV (14). While the origins of current VACV-like strains have been heavily debated and remain obscure, current knowledge affirms that VACV-like viruses constitute an OPV lineage independent of known CPXV and VARV species from which VACV has been speculated to be derived (14, 32, 33, 38) (Fig. 2). It is likely that a once naturally circulating but now rare VACV-like virus(s) from which current strains are derived was introduced as a vaccine virus, and the agent of horsepox has been surmised as a likely candidate (14). Indeed, apparently Edward Jenner believed that his vaccine originated from the “grease” infection found in the heels of horses, and the use of horse-derived material for use as vaccines is documented (14, 33). In addition, phenotypic similarity of certain vaccines transmitted between cows, humans, and horses has been noted, and experimental infection of horses with VACV can produce clinical signs of horsepox (14, 44, 86). The data presented here indicate that the HSPV MNR-76 genome contains features consistent with such a hypothesis, a phylogenetically VACV-like virus isolated from a horse and containing additional OPV-like terminal sequences, sequences likely ancestral and absent in other VACV-like viruses yet in certain regions appearing to be undergoing gene fragmentation and loss commensurate with transition toward a VACV-like genotype.

Despite speculation as to what role horsepox played in the development of smallpox vaccines, it is clear that HSPV MNR-76 does not represent a direct ancestral genotype to all known VACVs, given the disruption of many HSPV genes intact in certain VACV isolates (Table 1). It is unclear what constitutes the genotypic diversity of all the viruses historically used for smallpox vaccine, especially considering the potential for disparate source material and passage histories of VACV-like vaccine viruses (14, 33). Indeed, phenotypic and genotypic diversity is observed between and within strains of VACV (14, 33, 58) (Fig. 1). This diversity does include sequence unique to a given strain, such as the presence of CPXV GRI K3R and S1R/T1R-like genes in the historically important Lister vaccine strain (Fig. 1C), making the presence of HSPV MNR-76-like sequences in uncharacterized vaccine strains a possibility. Isolated in 1976, HSPV was causing disease in horses while smallpox vaccines were still being distributed during the World Health Organization global smallpox eradication program (32). Conceivably, local or a currently uncharacterized vaccine could have been introduced into the horse population, as contact with vaccinated persons is known to have been a source of OPV disease in animals (33). Vaccine escape has been hypothesized to account for other VACV-like viruses occasionally isolated from domestic and sentinel animals, including RPXV, buffalopox in India, and viruses associated with zoonosis in South America; however, unique biological properties and/or inability to associate the isolate with vaccine virus has also led to suggestions that they are natural VACV isolates or VACV subspecies (19, 24, 25, 27, 33, 46, 90). Similarly, HSPV MNR-76 may represent a novel, naturally circulating virus and perhaps one for which the horse was an incidental host, just as other domestic and captive animals are not thought to be the reservoir for CPXV infection despite being susceptible to infection (13, 33). Unfortunately, little is known of the prevalence of disease associated with HSPV MNR-76 in Mongolia, either in horse or in human populations. Conceivably, MNR-76 may represent a naturally circulating member of the VACV lineage, as were viruses circulating among domestic animals in the era in which current VACV-like viruses were collected as vaccine. Whatever the historical relationship between HSPV MNR-76 and characterized VACV-like viruses may be, genomic sequence analysis of other VACV-like virus isolates may add perspective to the novel nature of HSPV relative to other viruses within the VACV lineage.

ADDENDUM IN PROOF

Since completion of the analyses presented here, the genome sequences of several VACV clones derived from the Dryvax vaccine have become available. Preliminary analysis indicates that while most of the HSPV sequence reported here as absent in VACV was also absent in these clones, one (GenBank accession no. AY313848) contained nucleotide sequence and ORF fragments at the HSPV 197 locus, stressing the need for additional genomic sequence and analyses in examining the nature of VACV-like virus variability.

Acknowledgments

We thank A. Lakowitz and A. Waite Lund for excellent technical assistance.

REFERENCES

  • 1.Afonso, C. L., E. R. Tulman, Z. Lu, E. Oma, G. F. Kutish, and D. L. Rock. 1999. The genome of Melanoplus sanguinipes entomopoxvirus. J. Virol. 73:533-552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Afonso, C. L., E. R. Tulman, Z. Lu, L. Zsak, N. T. Sandybaev, U. Z. Kerembekova, V. L. Zaitsev, G. F. Kutish, and D. L. Rock. 2002. The genome of camelpox virus. Virology 295:1-9. [DOI] [PubMed] [Google Scholar]
  • 3.Albagli, O., P. Dhordain, C. Deweindt, G. Lecocq, and D. Leprince. 1995. The BTB/POZ domain: a new protein-protein interaction motif common to DNA- and actin-binding proteins. Cell Growth Differ. 6:1193-1198. [PubMed] [Google Scholar]
  • 4.Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50. [DOI] [PubMed] [Google Scholar]
  • 5.Alcami, A., A. Khanna, N. L. Paul, and G. L. Smith. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80:949-959. [DOI] [PubMed] [Google Scholar]
  • 6.Alcami, A., J. A. Symons, P. D. Collins, T. J. Williams, and G. L. Smith. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-633. [PubMed] [Google Scholar]
  • 7.Alejo, A., M. B. Ruiz-Arguello, Y. Ho, V. P. Smith, M. Saraiva, and A. Alcami. 2006. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc. Natl. Acad. Sci. USA 103:5995-6000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396. [DOI] [PubMed] [Google Scholar]
  • 10.Baroudy, B. M., and B. Moss. 1982. Sequence homologies of diverse length tandem repetitions near ends of vaccinia virus genome suggest unequal crossing over. Nucleic Acids Res. 10:5673-5679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Baroudy, B. M., S. Venkatensan, and B. Moss. 1982. Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell 28:315-324. [DOI] [PubMed] [Google Scholar]
  • 12.Barry, M., S. Hnatiuk, K. Mossman, S. F. Lee, L. Boshkov, and G. McFadden. 1997. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes. Virology 239:360-377. [DOI] [PubMed] [Google Scholar]
  • 13.Baxby, D. 1977. Is cowpox misnamed? A review of 10 human cases. Br. Med. J. 1:1379-1381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Baxby, D. 1981. Jenner's smallpox vaccine: the riddle of vaccinia virus and its origin. Heinemann Educational Books Ltd., London, United Kingdom.
  • 15.Brady, G., L. Boggan, A. Bowie, and L. A. O'Neill. 2005. Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1. J. Biol. Chem. 280:30723-30734. [DOI] [PubMed] [Google Scholar]
  • 16.Breman, J. G., and D. A. Henderson. 2002. Diagnosis and management of smallpox. N. Engl. J. Med. 346:1300-1308. [DOI] [PubMed] [Google Scholar]
  • 17.Brudno, M., M. Chapman, B. Gottgens, S. Batzoglou, and B. Morgenstern. 2003. Fast and sensitive multiple alignment of large genomic sequences. BMC Bioinformatics 4:66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Brudno, M., C. B. Do, G. M. Cooper, M. F. Kim, E. Davydov, E. D. Green, A. Sidow, and S. Batzoglou. 2003. LAGAN and Multi-LAGAN: efficient tools for large-scale multiple alignment of genomic DNA. Genome Res. 13:721-731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Buller, R. M., and G. J. Palumbo. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80-122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Castresana, J. 2000. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. Mol. Biol. Evol. 17:540-552. [DOI] [PubMed] [Google Scholar]
  • 21.Chen, N., M. I. Danila, Z. Feng, R. M. Buller, C. Wang, X. Han, E. J. Lefkowitz, and C. Upton. 2003. The genomic sequence of ectromelia virus, the causative agent of mousepox. Virology 317:165-186. [DOI] [PubMed] [Google Scholar]
  • 22.Chen, N., G. Li, M. K. Liszewski, J. P. Atkinson, P. B. Jahrling, Z. Feng, J. Schriewer, C. Buck, C. Wang, E. J. Lefkowitz, J. J. Esposito, T. Harms, I. K. Damon, R. L. Roper, C. Upton, and R. M. Buller. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340:46-63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Child, S. J., G. J. Palumbo, R. M. Buller, and D. E. Hruby. 1990. Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo. Virology 174:625-629. [DOI] [PubMed] [Google Scholar]
  • 24.da Fonseca, F. G., G. S. Trindade, R. L. Silva, C. A. Bonjardim, P. C. Ferreira, and E. G. Kroon. 2002. Characterization of a vaccinia-like virus isolated in a Brazilian forest. J. Gen. Virol. 83:223-228. [DOI] [PubMed] [Google Scholar]
  • 25.Damaso, C. R., J. J. Esposito, R. C. Condit, and N. Moussatche. 2000. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 277:439-449. [DOI] [PubMed] [Google Scholar]
  • 26.de Carlos, A., and E. Paez. 1991. Isolation and characterization of mutants of vaccinia virus with a modified 94-kDa inclusion protein. Virology 185:768-778. [DOI] [PubMed] [Google Scholar]
  • 27.de Souza Trindade, G., F. G. da Fonseca, J. T. Marques, M. L. Nogueira, L. C. Mendes, A. S. Borges, J. R. Peiro, E. M. Pituco, C. A. Bonjardim, P. C. Ferreira, and E. G. Kroon. 2003. Aracatuba virus: a vaccinialike virus associated with infection in humans and cattle. Emerg. Infect. Dis. 9:155-160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Essajee, S., and H. L. Kaufman. 2004. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 4:575-588. [DOI] [PubMed] [Google Scholar]
  • 29.Ewing, B., and P. Green. 1998. Base-calling of automated sequencer traces using Phred. II. Error probabilities. Genome Res. 8:186-194. [PubMed] [Google Scholar]
  • 30.Ewing, B., L. Hillier, M. C. Wendl, and P. Green. 1998. Base-calling of automated sequencer traces using Phred. I. Accuracy assessment. Genome Res. 8:175-185. [DOI] [PubMed] [Google Scholar]
  • 31.Felsenstein, J. 1989. PHYLIP—phylogeny inference package (version 3.2). Cladistics 5:164-166. [Google Scholar]
  • 32.Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
  • 33.Fenner, F., R. Wittek, and K. Dumbell. 1989. The orthopoxviruses. Academic Press, Inc., San Diego, Calif.
  • 34.Galtier, N., M. Gouy, and C. Gautier. 1996. SEAVIEW and PHYLO WIN: two graphic tools for sequence alignment and molecular phylogeny. Comput. Appl. Biol. Sci. 12:543-554. [DOI] [PubMed] [Google Scholar]
  • 35.Gardner, J. D., D. C. Tscharke, P. C. Reading, and G. L. Smith. 2001. Vaccinia virus semaphorin A39R is a 50-55 kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model. J. Gen. Virol. 82:2083-2093. [DOI] [PubMed] [Google Scholar]
  • 36.Goebel, S. J., G. P. Johnson, M. E. Perkus, S. W. Davis, J. P. Winslow, and E. Paoletti. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-266. [DOI] [PubMed] [Google Scholar]
  • 37.Gordon, D., C. Abajian, and P. Green. 1998. Consed: a graphical tool for sequence finishing. Genome Res. 8:192-202. [DOI] [PubMed] [Google Scholar]
  • 38.Gubser, C., S. Hue, P. Kellam, and G. L. Smith. 2004. Poxvirus genomes: a phylogenetic analysis. J. Gen. Virol. 85:105-117. [DOI] [PubMed] [Google Scholar]
  • 39.Gubser, C., and G. L. Smith. 2002. The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J. Gen. Virol. 83:855-872. [DOI] [PubMed] [Google Scholar]
  • 40.Guindon, S., and O. Gascuel. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52:696-704. [DOI] [PubMed] [Google Scholar]
  • 41.Hsiao, J. C., C. S. Chung, R. Drillien, and W. Chang. 2004. The cowpox virus host range gene, CP77, affects phosphorylation of eIF2 alpha and vaccinia viral translation in apoptotic HeLa cells. Virology 329:199-212. [DOI] [PubMed] [Google Scholar]
  • 42.Hu, F. Q., C. A. Smith, and D. J. Pickup. 1994. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204:343-356. [DOI] [PubMed] [Google Scholar]
  • 43.Huang, X., and A. Madan. 1999. CAP3: a DNA sequence assembly program. Genome Res. 9:868-877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Hutyra, F., J. Marek, and R. Manninger. 1949. Pox (variola), p. 348-393. In J. R. Greig (ed.), Special pathology and therapeutics of the diseases of domestic animals, vol. 1. Bailliere, Tindall and Cox, London, United Kingdom. [Google Scholar]
  • 45.Kochneva, G., I. Kolosova, T. Maksyutova, E. Ryabchikova, and S. Shchelkunov. 2005. Effects of deletions of kelch-like genes on cowpox virus biological properties. Arch. Virol. 150:1857-1870. [DOI] [PubMed] [Google Scholar]
  • 46.Kolhapure, R. M., R. P. Deolankar, C. D. Tupe, C. G. Raut, A. Basu, B. M. Dama, S. D. Pawar, M. V. Joshi, V. S. Padbidri, M. K. Goverdhan, and K. Banerjee. 1997. Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996. Indian J. Med. Res. 106:441-446. [PubMed] [Google Scholar]
  • 47.Kotwal, G. J., and B. Moss. 1988. Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology 167:524-537. [PubMed] [Google Scholar]
  • 48.Legrand, F. A., P. H. Verardi, L. A. Jones, K. S. Chan, Y. Peng, and T. D. Yilma. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Leite, J. A., B. P. Drumond, G. S. Trindade, Z. I. Lobato, F. G. da Fonseca, S. J. Dos, M. C. Madureira, M. I. Guedes, J. M. Ferreira, C. A. Bonjardim, P. C. Ferreira, and E. G. Kroon. 2005. Passatempo virus, a vaccinia virus strain, Brazil. Emerg. Infect. Dis. 11:1935-1938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lewis-Jones, S. 2004. Zoonotic poxvirus infections in humans. Curr. Opin. Infect. Dis. 17:81-89. [DOI] [PubMed] [Google Scholar]
  • 51.Li, G., N. Chen, R. L. Roper, Z. Feng, A. Hunter, M. Danila, E. J. Lefkowitz, R. M. Buller, and C. Upton. 2005. Complete coding sequences of the rabbitpox virus genome. J. Gen. Virol. 86:2969-2977. [DOI] [PubMed] [Google Scholar]
  • 52.Likos, A. M., S. A. Sammons, V. A. Olson, A. M. Frace, Y. Li, M. Olsen-Rasmussen, W. Davidson, R. Galloway, M. L. Khristova, M. G. Reynolds, H. Zhao, D. S. Carroll, A. Curns, P. Formenty, J. J. Esposito, R. L. Regnery, and I. K. Damon. 2005. A tale of two clades: monkeypox viruses. J. Gen. Virol. 86:2661-2672. [DOI] [PubMed] [Google Scholar]
  • 53.Massung, R. F., J. C. Knight, and J. J. Esposito. 1995. Topography of variola smallpox virus inverted terminal repeats. Virology 211:350-355. [DOI] [PubMed] [Google Scholar]
  • 54.Massung, R. F., L.-I. Liu, J. Qi, J. C. Knight, T. E. Yuran, A. R. Kerlavage, J. M. Parsons, J. C. Venter, and J. J. Esposito. 1994. Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 201:215-240. [DOI] [PubMed] [Google Scholar]
  • 55.Merchlinsky, M., and B. Moss. 1989. Nucleotide sequence required for resolution of the concatemer junction of vaccinia virus DNA. J. Virol. 63:4354-4361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Meyer, H., A. Totmenin, E. Gavrilova, and S. Shchelkunov. 2005. Variola and camelpox virus-specific sequences are part of a single large open reading frame identified in two German cowpox virus strains. Virus Res. 108:39-43. [DOI] [PubMed] [Google Scholar]
  • 57.Morgenstern, B., K. Frech, A. Dress, and T. Werner. 1998. DIALIGN: finding local similarities by multiple sequence alignment. Bioinformatics 14:290-294. [DOI] [PubMed] [Google Scholar]
  • 58.Morikawa, S., T. Sakiyama, H. Hasegawa, M. Saijo, A. Maeda, I. Kurane, G. Maeno, J. Kimura, C. Hirama, T. Yoshida, Y. Asahi-Ozaki, T. Sata, T. Kurata, and A. Kojima. 2005. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J. Virol. 79:11873-11891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Moss, B. 2001. Poxviridae: the viruses and their replication, p. 2849-2883. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa. [Google Scholar]
  • 60.Moss, B., and J. L. Shisler. 2001. Immunology 101 at poxvirus U: immune evasion genes. Semin. Immunol. 13:59-66. [DOI] [PubMed] [Google Scholar]
  • 61.Moyer, R. W., and R. L. Graves. 1981. The mechanism of cytoplasmic orthopoxvirus DNA replication. Cell 27:391-401. [DOI] [PubMed] [Google Scholar]
  • 62.Nylander, J. A. A. 2004. MrModeltest 2.2. Evolutionary Biology Centre, Uppsala University, Uppsala, Sweden.
  • 63.Panus, J. F., C. A. Smith, C. A. Ray, T. D. Smith, D. D. Patel, and D. J. Pickup. 2002. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. Proc. Natl. Acad. Sci. USA 99:8348-8353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Pearson, W. R. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. Methods Enzymol. 183:63-98. [DOI] [PubMed] [Google Scholar]
  • 65.Pearson, W. R., and D. J. Lipman. 1988. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444-2448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Pearson, W. R., T. Wood, Z. Zhang, and W. Miller. 1997. Comparison of DNA sequences with protein sequences. Genomics 46:24-36. [DOI] [PubMed] [Google Scholar]
  • 67.Perkus, M. E., S. J. Goebel, S. W. Davis, G. P. Johnson, K. Limbach, E. K. Norton, and E. Paoletti. 1990. Vaccinia virus host range genes. Virology 179:276-286. [DOI] [PubMed] [Google Scholar]
  • 68.Price, N., D. C. Tscharke, and G. L. Smith. 2002. The vaccinia virus B9R protein is a 6 kDa intracellular protein that is non-essential for virus replication and virulence. J. Gen. Virol. 83:873-878. [DOI] [PubMed] [Google Scholar]
  • 69.Reed, K. D., J. W. Melski, M. B. Graham, R. L. Regnery, M. J. Sotir, M. V. Wegner, J. J. Kazmierczak, E. J. Stratman, Y. Li, J. A. Fairley, G. R. Swain, V. A. Olson, E. K. Sargent, S. C. Kehl, M. A. Frace, R. Kline, S. L. Foldy, J. P. Davis, and I. K. Damon. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350:342-350. [DOI] [PubMed] [Google Scholar]
  • 70.Rice, P., I. Longden, and A. Bleasby. 2000. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet. 16:276-277. [DOI] [PubMed] [Google Scholar]
  • 71.Salzberg, S. L., A. L. Delcher, S. Kasif, and O. White. 1998. Microbial gene identification using interpolated Markov models. Nucleic Acids Res. 26:544-548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Saraiva, M., P. Smith, P. G. Fallon, and A. Alcami. 2002. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med. 196:829-839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Schmidt, H. A., K. Strimmer, M. Vingron, and A. von Haeseler. 2002. TREE-PUZZLE: maximum likelihood phylogenetic analysis using quartets and parallel computing. Bioinformatics 18:502-504. [DOI] [PubMed] [Google Scholar]
  • 74.Senkevich, T. G., E. J. Wolffe, and R. M. L. Buller. 1995. Ectromelia virus RING finger protein is localized in virus factories and is required for virus replication in macrophages. J. Virol. 69:4103-4111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Shchelkunov, S., A. Totmenin, and I. Kolosova. 2002. Species-specific differences in organization of orthopoxvirus kelch-like proteins. Virus Genes 24:157-162. [DOI] [PubMed] [Google Scholar]
  • 76.Shchelkunov, S. N., V. M. Blinov, S. M. Resenchuk, A. V. Totmenin, L. V. Olenina, G. B. Chirikova, and L. S. Sandakhchiev. 1994. Analysis of the nucleotide sequence of 53 kbp from the right terminus of the genome of variola major virus strain India-1967. Virus Res. 34:207-236. [DOI] [PubMed] [Google Scholar]
  • 77.Shchelkunov, S. N., V. M. Blinov, and L. S. Sandakhchiev. 1993. Ankyrin-like proteins of variola and vaccinia viruses. FEBS Lett. 319:163-165. [DOI] [PubMed] [Google Scholar]
  • 78.Shchelkunov, S. N., R. F. Massung, and J. J. Esposito. 1995. Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. Virus Res. 36:107-118. [DOI] [PubMed] [Google Scholar]
  • 79.Shchelkunov, S. N., P. F. Safronov, A. V. Totmenin, N. A. Petrov, O. I. Ryazankina, V. V. Gutorov, and G. J. Kotwal. 1998. The genome sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology 243:432-460. [DOI] [PubMed] [Google Scholar]
  • 80.Shchelkunov, S. N., A. V. Totmenin, V. N. Loparev, P. F. Safronov, V. V. Gutorov, V. E. Chizhikov, J. C. Knight, J. M. Parsons, R. F. Massung, and J. J. Esposito. 2000. Alastrim smallpox variola minor virus genome DNA sequences. Virology 266:361-386. [DOI] [PubMed] [Google Scholar]
  • 81.Shchelkunov, S. N., A. V. Totmenin, P. F. Safronov, M. V. Mikheev, V. V. Gutorov, O. I. Ryazankina, N. A. Petrov, I. V. Babkin, E. A. Uvarova, L. S. Sandakhchiev, J. R. Sisler, J. J. Esposito, I. K. Damon, P. B. Jahrling, and B. Moss. 2002. Analysis of the monkeypox virus genome. Virology 297:172-194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Shisler, J. L., and B. Moss. 2001. Immunology 102 at poxvirus U: avoiding apoptosis. Semin. Immunol. 13:67-72. [DOI] [PubMed] [Google Scholar]
  • 83.Smith, G. L., and G. McFadden. 2002. Smallpox: anything to declare? Nat. Rev. Immunol. 2:521-527. [DOI] [PubMed] [Google Scholar]
  • 84.Sonnhammer, E. L., and R. Durbin. 1995. A dot-matrix program with dynamic threshold control suited for genomic DNA and protein sequence analysis. Gene 167:GC1-GC10. [DOI] [PubMed] [Google Scholar]
  • 85.Spehner, D., S. Gillard, R. Drillien, and A. Kirn. 1988. A cowpox virus gene required for multiplication in Chinese hamster ovary cells. J. Virol. 62:1297-1304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Studdert, M. J. 1989. Experimental vaccinia virus infection of horses. Aust. Vet. J. 66:157-159. [DOI] [PubMed] [Google Scholar]
  • 87.Taylor, J. M., and M. Barry. 2006. Near death experiences: poxvirus regulation of apoptotic death. Virology 344:139-150. [DOI] [PubMed] [Google Scholar]
  • 88.Thompson, C. H., J. A. Yager, and I. B. Van Rensburg. 1998. Close relationship between equine and human molluscum contagiosum virus demonstrated by in situ hybridisation. Res. Vet. Sci. 64:157-161. [DOI] [PubMed] [Google Scholar]
  • 89.Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Trindade, G. S., F. G. da Fonseca, J. T. Marques, S. Diniz, J. A. Leite, S. De Bodt, Y. Van der Peer, C. A. Bonjardim, P. C. Ferreira, and E. G. Kroon. 2004. Belo Horizonte virus: a vaccinia-like virus lacking the A-type inclusion body gene isolated from infected mice. J. Gen. Virol. 85:2015-2021. [DOI] [PubMed] [Google Scholar]
  • 91.Upton, C., L. Schiff, S. A. Rice, T. Dowdeswell, X. Yang, and G. McFadden. 1994. A poxvirus protein with a RING finger motif binds zinc and localizes in virus factories. J. Virol. 68:4186-4195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Upton, C., S. Slack, A. L. Hunter, A. Ehlers, and R. L. Roper. 2003. Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J. Virol. 77:7590-7600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Wesley, R. D., and A. E. Tuthill. 1984. Genome relatedness among African swine fever virus field isolates by restriction endonuclease analysis. Prev. Vet. Med. 2:53-62. [Google Scholar]
  • 94.Yager, J. A., D. W. Scott, and B. P. Wilcock. 1993. The skin and appendages, p. 531-738. In K. V. F. Jubb, P. C. Kennedy, and N. Palmer (ed.), Pathology of domestic animals, 4th ed., vol. 1. Academic Press, San Diego, Calif. [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES